Quest Diagnostics Stock News

Veriti Management LLC boosted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 39.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,476 shares of the medical research companys stock after acquiring an additional 1,541 shares during the quarter. Veriti Management LLCs []

With the Biden administration making the move to open U.S. land borders with Canada and Mexico, these stocks to buy can get a boost. The post 7 Stocks to Buy as America Lifts Its Travel Ban appeared f

Quest Diagnostics beat analysts' estimates in the third quarter and raised its guidance for this year again.

DUBLIN--(BUSINESS WIRE)--The "Lung Cancer Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com''s offering. Amid the COVID-19 crisis, the global market for Lung Cancer Diagnostics estimated at US$2.5 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 8.1% over the analysis period 2020-2027. Imaging Tests, one of the segments analyzed in the report, is projected to grow at a 8% CAGR to r

Two-thirds of primary care doctors worried they missed signs of addiction in their patients, Quest Diagnostics found To view the full story, click the title link.

Kidney Function Tests is also known as Renal Function Test. The kidneys play a vital role in the excretion of waste products and toxins such as urea, creatinine and uric acid, regulation of extracellular fluid volume, serum osmolality and electrolyte

As announced, Stratagem Market Insights will introduce At-Home Genetic Testing Market Overview 2021 Research Report. SMI said, there is "substantial chance" that the in-depth introduction will be get by At-Home Genetic Testing Market Report. The report incorporates detailed market segmentation,

Key Prominent Players Covered in the US Genetic Testing Market are Invitae Corporation (San Francisco, U.S.), Ambry Genetics (Aliso Viejo, U.S.), BioReference Laboratories, Inc. (Elmwood Park, U.S.), Progenity, Inc. (San Diego, U.S.), Quest Diagnostics Incorporated (Secaucus, U.S.), Myriad Genetics, Inc. (Salt Lake City, U.S.), Fulgent Genetics (Temple City, U.S.), Burning Rock Biotech Limited (Guangzhou, China) Key Prominent Players Covered in the US Genetic Testing Market are Invitae Corporation (San Francisco, U.S.), Ambry Genetics (Aliso Viejo, U.S.), BioReference Laboratories, Inc. (Elmwood Park, U.S.), Progenity, Inc. (San Diego, U.S.), Quest Diagnostics Incorporated (Secaucus, U.S.), Myriad Genetics, Inc. (Salt Lake City, U.S.), Fulgent Genetics (Temple City, U.S.), Burning Rock Biotech Limited (Guangzhou, China)

SECAUCUS, N.J., Nov. 15, 2021 /PRNewswire/ -- A new Health Trends® report from Quest Diagnostics (NYSE: DGX) finds that almost 70% of physicians fear they missed signs of drug misuse during the pandemic, and, given how the global health crisis disrupted medical care, anticipate rising

B. Metzler seel. Sohn & Co. Holding AG cut its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 17.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,693 shares of the medical research companys stock after selling 3,556 shares during the quarter. []

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Here are five stocks, OLN, DGX, EQNR, TECK, and GS that qualify the screening.

Quest Diagnostics (DGX) has been struggling lately, but the selling pressure may be coming to an end soon.